mometasone furoate (mometasone)

01/01/2001 - "Mometasone furoate 200 microg twice daily or 400 microg once daily in the morning or 200 microg once daily in the evening improved lung function, asthma symptom scores and use of rescue medication to a significantly greater extent than placebo in patients who had previously received only short-acting inhaled beta2-adrenoceptor agonists alone as treatment in 3 trials (n = 195 to 306). "
11/01/2006 - "Both mometasone furoate DPI doses were well tolerated and significantly improved lung function, maintained effective asthma control, and improved quality of life in children with asthma."
01/01/2006 - "Inhaled mometasone furoate is equally effective in controlling asthma when administered in two divided doses or as a single daily dose. "
09/01/2000 - "Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma."
12/01/2011 - "A literature search using PubMed was done using the terms 'mometasone furoate', 'inhaled corticosteroid' and 'asthma', focusing on articles that highlighted clinical trials and addressed efficacy of the medication. "

10/01/2008 - "Several randomized, double-blind, placebo-controlled clinical trials have demonstrated the efficacy of mometasone furoate nasal spray (MFNS) in the treatment of allergic rhinitis (AR) thus allowing for a meta-analysis to determine the overall treatment effect. "
11/07/2005 - "The results indicated that mometasone is effective in allergic rhinitis, not only during the period of application, but also after the interruption of application."
04/01/2005 - "We found that mometasone furoate nasal spray was effective against experimentally induced rhinitis medicamentosa in guinea pigs. "
04/01/2003 - "Mometasone furoate nasal spray was effective in controlling allergic rhinitis and was well tolerated by patients."
07/01/2001 - "Intranasal mometasone furoate (MF) has been extensively studied in adults and has been found to be safe and effective therapy for the treatment of allergic rhinitis. "

07/01/2014 - "Mometasone furoate as a nasal spray is an effective treatment for seasonal allergic rhinitis (SAR). "
05/01/2012 - "These preliminary findings suggest that mometasone furoate nasal spray effectively treats itchy ear and palate in individuals with seasonal allergic rhinitis. "
05/01/1999 - "Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting."
08/18/2002 - "These results demonstrate that mometasone furoate nasal spray is a safe and effective intranasal corticosteroid for the therapy of SAR/SARC seasonal allergic rhinitis and rhinoconjunctivitis."
07/01/2014 - "Comparative safety and efficacy of two formulations of mometasone nasal spray in adult seasonal allergic rhinitis."

07/01/2010 - "However, mometasone furoate NS therapy significantly improved morning (P = .04) and evening (P = .01) TNSSs, morning (P = .049) and evening (P = .03) nasal obstruction/blockage/congestion, daily peak nasal inspiratory flow (P = .03), flow limitation index (P = .02), Epworth Sleepiness Scale score (P = .048), RQLQ-S score (P = .03), and 2 of 5 WPAI-AS domains. "
06/01/2012 - "This study aims to evaluate the effects of topical mometasone treatment on symptoms and size of adenoid tissue in children with complaints of nasal obstruction and to compare this approach to continuous nasal saline douching plus environmental control alone. "
12/01/2011 - "Powered-assisted partial turbinectomy versus mometasone furoate nasal spray for relief of nasal blockage in chronic or idiopathic rhinosinusitis."
01/01/2008 - "The third randomized, parallel-group trial showed that 77.7% of patients treated with mometasone (100 micrograms/day) for 40 days demonstrated an improvement in nasal obstruction symptoms and a decrease in adenoid size, such that adenoidectomy could be avoided, whereas no significant improvement was observed in the placebo group. "
03/01/2010 - "After ineffective revision sinus surgery and prolonged mometasone furoate application, 19 consecutive mild and moderate NP patients suffering from nasal obstruction (NO) and olfactory dysfunction (OD) were prospectively entered into the study to undergo DLPE under topical anesthesia. "

10/01/1998 - "In several large, well-controlled clinical trials, mometasone furoate 200 micrograms administered once daily as an aqueous intranasal spray was significantly more effective than placebo in controlling the symptoms associated with moderate to severe seasonal or perennial allergic rhinitis. "
05/01/2009 - "Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis."
03/01/2012 - "We prospectively investigated the efficacy of mometasone furoate nasal spray (MFNS) for improving the total nasal symptom score, QOL score, and sleep quality in subjects with perennial allergic rhinitis (PAR). "
01/01/2013 - "Relieving nasal congestion in children with seasonal and perennial allergic rhinitis: efficacy and safety studies of mometasone furoate nasal spray."
02/01/2000 - "A 1-year study of prepubertal patients between 3 and 9 years of age with perennial allergic rhinitis was conducted to assess the effects on growth of mometasone furoate aqueous nasal spray (MFNS), a new once-daily (QD) intranasal corticosteroid with negligible bioavailability. "